# Vitiligo FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/vitiligo

> 6 upcoming FDA catalysts in vitiligo: Litfulo (ritlecitinib tosylate, PFE) on Mar to Jun 2027 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on March 2027 (primary completion); RINVOQ® (upadacitinib, ABBV) on March 2028 (primary completion); RINVOQ® (upadacitinib, ABBV) on Mar to Jun 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar to Jun 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Vitiligo | scheduled | "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06163326)) |
| March 2027 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Vitiligo | scheduled | "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06163326)) |
| March 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Vitiligo | scheduled | "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118411)) |
| Mar to Jun 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Vitiligo | scheduled | "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118411)) |
| Sep to Dec 2030 | [Tev-53408 dose a topline data readout](https://sec-api.dev/pdufa/tev-53408) | TEVA | Vitiligo | scheduled | "NCT07920211 (Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09-12 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920211)) |
| September 2030 | [Tev-53408 dose a primary completion](https://sec-api.dev/pdufa/tev-53408) | TEVA | Vitiligo | scheduled | "NCT07920211 (Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09-12 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07920211)) |

## Drugs

- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Tev-53408 dose a](https://sec-api.dev/pdufa/tev-53408) (TEVA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/vitiligo.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vitiligo FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/vitiligo

```bibtex
@misc{secapidev_indications_vitiligo_20261116,
  title        = {Vitiligo FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/vitiligo}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_vitiligo_20261116","title":"Vitiligo FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/vitiligo","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
